about
State of the art: Oral antiplatelet therapyImpact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitorsPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsFirst-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patientsLeft ventricle systolic volume in vasovagal syncope patients.[Advantages and controversies regarding physiologic electrostimulation of the heart in sinus node disease].The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Cangrelor: an emerging therapeutic option for patients with coronary artery disease.Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.Value of oral glucose tolerance test in the acute phase of myocardial infarctionMeta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trialUsefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction.Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysisValue of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile.Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials.ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience.Influence of plaque morphology on the mechanism of luminal enlargement after directional coronary atherectomy and balloon angioplasty.High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cellsSafety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies.Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae.Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation.Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions.Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials.Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.A critical overview on ticagrelor in acute coronary syndromes.Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.Management of atrial fibrillation in the Emergency Department: current approach and future expectations.Off-target effects of glycoprotein IIb/IIIa receptor inhibitors.Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients.Critical appraisal of inflammatory markers in cardiovascular risk stratification.
P50
Q26746161-D0510EC9-43D9-4D6F-AAAA-D7134DFCB500Q26748904-589C39D7-764A-4913-945F-C45A78A8D92CQ26775125-DBC95836-C739-428D-BE09-41EA7692340FQ28543594-3E235451-CAE3-4586-8132-49F27AEDB927Q33150552-84CA87AB-53FD-477B-B9BB-4650F795B4D3Q33174656-459749D4-F4E4-4929-BE42-744E99907EC5Q33892516-999A6B22-654E-4CAB-B7DC-C26DB2E227D5Q33933475-6E62F5A2-2C36-4BD9-9BC7-24EFE3138659Q34395970-027B610E-0D38-44BD-ABBC-1D07AADF2299Q34473809-C735DCF3-F96E-4B27-A57F-9A3320BA647BQ34708441-A1397336-9DEB-44B6-80CD-2237402C12F3Q35162424-1A79F1A0-305C-4656-8648-61455ADFC32FQ35584168-32299C54-8921-4790-98EC-C9467CD71282Q36031419-2DC116F1-EB51-4782-8EF6-F2727094B83AQ36225152-8B83BE96-833C-490D-8469-27EA8BE6ED2EQ36267436-F2E000EC-134A-40D4-B67C-A17997FBB56EQ36344191-894CB75C-46EC-4B37-9062-6E369909253CQ36460862-E7A3064B-89FC-4690-B04A-1C50655EC9BDQ36695192-B776105E-9A0B-4A82-B1DE-AE51D9F0884CQ36734920-DA3069A7-10D8-4D03-AE17-420763A678BCQ36822613-872062A4-F320-44A2-A762-6BE338C76E21Q36948503-2B844B8D-7ED1-4E17-815C-6853A0BD78BAQ37284036-A2A26892-3927-4392-9267-9CC329154C1CQ37653189-C8147BE1-16BC-4339-A598-3A2F7DC8D9C4Q37782184-A4506706-0B15-41D3-84E6-C2DF6C7850D0Q37832057-C10D10BF-AEC8-458E-B441-EA97384FBDDAQ37838335-E869477C-C356-4595-AE45-DA26059BF80DQ37861805-221BC84F-0BF1-4FD3-8023-E17F12BCC53DQ37868802-B4A04E19-4761-4CBC-AA2A-8BBE5395FE8DQ37875612-AD090741-0D86-44B7-B137-FE43009781FBQ37937603-65C741CC-5DA9-4033-9ECA-7BC639529BE3Q37966223-116EECA9-6500-457A-A5A1-203CF6E3E5C9Q38014002-350BFED9-43CD-4159-82A8-6D7FEF479758Q38055461-E35D0360-13D1-4284-834E-F81497BBE0F3Q38082692-BCD45B16-34F8-4B0D-9878-EAE61B5BE2E5Q38106778-683CE344-4191-4D6A-A7EB-08F6D523D70AQ38171368-0A4429F3-5AEC-4E93-94FE-EB0EE1DC3A97Q38187933-22F0FE6F-D9C0-4AA3-9FED-CA5873621EF3Q38188134-47DC1E43-AB32-4B1D-B35E-7AD751B13F0AQ38219501-CF42BDEB-FF26-4707-9A93-65987BCDB2C3
P50
description
Polish internist and cardiologist
@en
Pools onderzoeker
@nl
polski lekarz, internista, kardiolog
@pl
հետազոտող
@hy
name
Jacek Kubica
@ast
Jacek Kubica
@ca
Jacek Kubica
@cs
Jacek Kubica
@en
Jacek Kubica
@es
Jacek Kubica
@fr
Jacek Kubica
@gl
Jacek Kubica
@hr
Jacek Kubica
@hsb
Jacek Kubica
@it
type
label
Jacek Kubica
@ast
Jacek Kubica
@ca
Jacek Kubica
@cs
Jacek Kubica
@en
Jacek Kubica
@es
Jacek Kubica
@fr
Jacek Kubica
@gl
Jacek Kubica
@hr
Jacek Kubica
@hsb
Jacek Kubica
@it
prefLabel
Jacek Kubica
@ast
Jacek Kubica
@ca
Jacek Kubica
@cs
Jacek Kubica
@en
Jacek Kubica
@es
Jacek Kubica
@fr
Jacek Kubica
@gl
Jacek Kubica
@hr
Jacek Kubica
@hsb
Jacek Kubica
@it
P214
P106
P1153
7006463778
P1412
P1559
Jacek Kubica
@pl
P21
P213
0000 0000 7205 7330
P214
P27
P31
P3124
P496
0000-0001-8250-754X
P734
P735
P7859
viaf-102001176